

FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users

August 2015

ATTORNEYS

Landmon, Chad

Ropka, PhD, Stacie

PRACTICE AREAS

FDA

Intellectual Property

Stacie Ropka, PhD and Chad Landmon

GxP Lifeline

Axinn Counsel Stacie Ropka and Partner Chad Landmon authored, "FDA Regulation of CT/Ps – Impact of New Guidances on Manufacturers and Users," which was published in MasterControl's GxP Lifeline newsletter.

[Click here to read the article.](#)